« Return to News | R&D Trends

Covance to be exclusive drug development provider for BioPontis

Friday, February 3, 2012 01:25 PM

Covance has signed a three-year, exclusive integrated drug development agreement with BioPontis Alliance to manage early development of scientific discoveries from academia. Covance will become BioPontis Alliance’s sole provider of drug development services, including discovery support, pre-clinical, bioanalytical, CMC, clinical, central labs and commercialization.

“We are excited to take this unprecedented step forward with Covance as our translational development partner,” said Richard Basile, CEO and principal of BioPontis Alliance. “Together, with our university and industry partners, we have established a new development model to fuel biopharma’s early stage pipeline and accelerate the availability of new medicines.”


In this unique early development model, Covance will integrate and manage the services required to move a compound from lead optimization into the clinic, providing the scientific and operational continuity that reduces the feasibility gap between academic intellectual property and human proof of concept.

“Designing customized solutions that meet the unique needs of each client is the hallmark of our partnering philosophy,” said John Watson, chief commercial officer and president, strategic partnering, Covance. “This collaboration creates a new way for Covance to leverage our scientific expertise and broad portfolio of drug development services to advance the promising science of academia and deliver greater medical innovation to the biopharmaceutical industry.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.